Page 2207 - Williams Hematology ( PDFDrive )

2182 Part XII: Hemostasis and Thrombosis <CN>: von Willebrand Disease PB

322. Viallard JF, Pellegrin JL, Vergnes C, et al: Three cases of acquired von Willebrand 339. Castaman G, Lethagen S, Federici AB, et al: Response to desmopressin is influenced by
disease associated with systemic lupus erythematosus. Br J Haematol 105:532–537, the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the
1999. European Study MCMDM-1VWD. Blood 111:3531–3539, 2008.
323. Scott JP, Montgomery RR, Tubergen DG, Hays T: Acquired von Willebrand’s disease 340. Mannucci PM, Bettega D, Cattaneo M: Patterns of development of tachyphylaxis in
in association with Wilm’s tumor: Regression following treatment. Blood 58:665–669, patients with haemophilia and von Willebrand disease after repeated doses of desmo-
1981. pressin (DDAVP). Br J Haematol 82:87–93, 1992.
324. Warkentin TE, Moore JC, Morgan DG: Aortic stenosis and bleeding gastrointestinal 341. Federici AB, Mazurier C, Berntorp E, et al: Biologic response to desmopressin in
angiodysplasia: Is acquired von Willebrand’s disease the link? Lancet 340:35–37, 1992. patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter
325. Geisen U, Heilmann C, Beyersdorf F, et al: Non-surgical bleeding in patients with ven- European study. Blood 103:2032–2038, 2004.
tricular assist devices could be explained by acquired von Willebrand disease. Eur J 342. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW: Response of patients with mild and
Cardiothorac Surg 33:679–684, 2008. moderate hemophilia A and von Willebrand’s disease to treatment with desmopressin.
326. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F: Characterization of two cases Ann Intern Med 103:6–14, 1985.
of acquired transitory von Willebrand syndrome with ciprofloxacin: Evidence for 343. Gralnick HR, Williams SB, McKeown LP, et al: DDAVP in type IIa von Willebrand’s
heightened proteolysis of von Willebrand factor. Am J Hematol 49:83–86, 1995. disease. Blood 67:465–468, 1986.
327. Tefferi A, Nichols WL: Acquired von Willebrand disease: Concise review of occurrence, 344. Mannucci PM: Treatment of von Willebrand’s disease. N Engl J Med 351:683–694, 2004.
diagnosis, pathogenesis, and treatment. Am J Med 103:536–540, 1997. 345. Casonato A, Sartori MT, De Marco L, Girolami A: 1-Desamino-8-D-arginine vaso-
328. Kumar S, Pruthi RK, Nichols WL: Acquired von Willebrand disease. Mayo Clin Proc pressin (DDAVP) infusion in type IIB von Willebrand’s disease: Shortening of bleed-
77:181–187, 2002. ing time and induction of a variable pseudothrombocytopenia. Thromb Haemost 64:
329. Kanakry JA, Gladstone DE: Maintaining hemostasis in acquired von Willebrand syn- 117–120, 1990.
drome: A review of intravenous immunoglobulin and the importance of rituximab 346. McKeown LP, Connaghan G, Wilson O, et al: 1-Desamino-8-arginine-vasopressin cor-
dose scheduling. Transfusion 53:1730–1735, 2013. rects the hemostatic defects in type 2B von Willebrand’s disease. Am J Hematol 51:
330. Svensson PJ, Bergqvist PB, Juul KV, Berntorp E: Desmopressin in treatment of haema- 158–163, 1996.
tological disorders and in prevention of surgical bleeding. Blood Rev 28:95–102, 2014. 347. Mazurier C, Gaucher C, Jorieux S, Goudemand M: Biological effect of desmopressin
331. Abshire TC, Federici AB, Alvarez MT, et al: Prophylaxis in severe forms of von Wille- in eight patients with type 2N (“Normandy”) von Willebrand disease. Collaborative
brand’s disease: Results from the von Willebrand Disease Prophylaxis Network (VWD Group. Br J Haematol 88:849–854, 1994.
PN). Haemophilia 19:76–81, 2013. 348. Mannucci PM, Kempton C, Millar C, et al: Pharmacokinetics and safety of a novel
332. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A: 1-Deamino-8-d-arginine vaso- recombinant human von Willebrand factor manufactured with a plasma-free method:
pressin: A new pharmacological approach to the management of haemophilia and von A prospective clinical trial. Blood 122:648–657, 2013.
Willebrands’ diseases. Lancet 1:869–872, 1977. 349. Morfini M, Mannucci PM, Tenconi PM, et al: Pharmacokinetics of monoclonally-
333. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS: Multimeric purified and recombinant factor VIII in patients with severe von Willebrand disease.
composition of factor VIII/von Willebrand Factor following administration of DDAVP: Thromb Haemost 70:270–272, 1993.
Implications for pathophysiology and therapy of von Willebrand’s disease subtypes. 350. Makris M, Colvin B, Gupta V, et al: Venous thrombosis following the use of interme-
Blood 59:1272–1278, 1982. diate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb
334. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: The Haemost 88:387–388, 2002.
first 20 years. Blood 90:2515–2521, 1997. 351. Mannucci PM, Chediak J, Hanna W, et al: Treatment of von Willebrand disease with a
335. Federici AB, Mazurier C, Berntorp E, et al: Biologic response to desmopressin in high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter
patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter study. Blood 99:450–456, 2002.
European study. Blood 103:2032–2038, 2004. 352. Coppola A, Franchini M, Makris M, et al: Thrombotic adverse events to coagulation
336. Lethagen S, Harris AS, Nilsson IM: Intranasal desmopressin (DDAVP) by spray in mild factor concentrates for treatment of patients with haemophilia and von Willebrand dis-
hemophilia A and von Willebrand’s disease type I. Blut 60:187–191, 1990. ease: A systematic review of prospective studies. Haemophilia 18:e173–e187, 2012.
337. Rose EH, Aledort LM: Nasal spray desmopressin (DDAVP) for mild hemophilia A and 353. James AH, Konkle BA, Kouides P, et al: Postpartum von Willebrand factor levels in
von Willebrand disease. Ann Intern Med Intern Med 114:563–568, 1991. women with and without von Willebrand disease and implications for prophylaxis.
338. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M: Consistency of responses to Haemophilia 21:81–87, 2015.
repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia 354. Sucker C, Scharf RE, Zotz RB: Use of recombinant factor VIIa in inherited and acquired
A. Blood 74:1997–2000, 1989. von Willebrand disease. Clin Appl Thromb Hemost 15:27–31, 2009.

Kaushansky_chapter 126_p2163-2182.indd 2182 9/21/15 3:15 PM